A small naming difference can be important
FDA distinguishes semaglutide sodium and semaglutide acetate from the active ingredient used in approved semaglutide medicines. A seller may emphasize the shared word semaglutide while leaving the rest of the ingredient name less visible. Ask for the complete ingredient identity. The purpose is not to make a consumer a chemist; it is to avoid treating different named substances as interchangeable without evidence.[1]
The regulator’s concern is specific
FDA says it is not aware of a basis for compounding with these salt forms that meets the applicable conditions for active ingredients. This is more precise than a blanket statement that every medicine containing a salt is problematic. Many drug names include chemical forms, but the relevant question here is the specific semaglutide ingredient and the evidence and regulatory framework that apply to it.[2]
Do not generalize the warning to unrelated products
An approved medicine may use a different active ingredient with its own chemical form and reviewed formulation. That does not resolve the semaglutide-salt question, nor does the semaglutide warning establish a rule about every pharmaceutical salt. Read ingredient-specific statements in their actual scope. Similar chemistry terminology across two products does not make the regulatory evidence the same.
Ask the pharmacy rather than infer from marketing
Request the full prescription ingredient information from the dispensing pharmacy and ask the prescriber to explain the proposed product. If a website uses only a broad phrase such as “GLP-1 treatment,” that is not enough to determine what will be dispensed. Keep the written answer with the prescription record. A marketing image or a generic FAQ cannot replace the actual product information.
A certificate does not settle every question
A supplier may present a certificate or laboratory result as reassurance. Ask exactly what material was tested, which characteristics were measured and how it relates to the dispensed preparation. Even a genuine test for one property does not establish approval, clinical equivalence or every aspect of quality. Avoid allowing a single document to answer questions outside its scope.
Base-form wording is not an automatic endorsement
Even if a preparation uses the base form, that alone does not make the compounded medicine FDA approved. Ingredient identity, finished-product quality and appropriateness for a patient are separate questions. FDA explains that compounded medicines do not undergo its premarket review. The prescriber should explain the medical need being addressed rather than treating one acceptable-sounding ingredient term as the entire evaluation.[1]
Keep this distinction in oral comparisons too
A different route or added ingredient does not make the identity question disappear. If considering drops, a lozenge or another preparation, ask for both the ingredient and formulation. Evidence from an approved injected or swallowed product cannot simply be borrowed to establish the performance of something else. Product verification should precede price comparison. Related reading: oral tablets versus compounded drops.
Questions worth resolving before payment
Write down the complete ingredient, dosage form, dispensing pharmacy and reason the product is proposed. Ask which evidence supports the actual preparation and whether an approved option can meet the need. If the answers remain unclear, return to the clinician or pharmacist for clarification. A consumer review can organize these questions but cannot certify a compounded product from a public webpage. Related reading: branded versus compounded products.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
Prices and terms can change. Confirm your specific offer directly with the provider.